Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients
13th September 2021 Uncategorised 0AZ’s combo treatment reduced the risk of disease progression or death by 28% compared to chemotherapy alone
More: Imfinzi, tremelimumab combo boosts survival outcomes for NSCLC patients
Source: News
